Hillegonda Groen - Brainsway Vice Sales
| BWAY Stock | USD 9.87 0.19 1.96% |
Executive
Hillegonda Groen is Vice Sales of Brainsway
| Age | 55 |
| Address | Bynet Building, Jerusalem, Israel, 9777518 |
| Phone | 972 2 582 4030 |
| Web | https://www.brainsway.com |
Brainsway Management Efficiency
Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to drop to -0.1 in 2024. At this time, Brainsway's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.8 M in 2024, whereas Total Assets are likely to drop slightly above 42.3 M in 2024. Brainsway's management efficiency ratios could be used to measure how well Brainsway manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Esq | Tandem Diabetes Care | 54 | |
| Ben Sorci | Penumbra | N/A | |
| Angela Wiczek | Insulet | N/A | |
| John JD | Insulet | 64 | |
| Alon Yaari | InMode | N/A | |
| Andrew Isaacson | Insulet | N/A | |
| June Lazaroff | Insulet | N/A | |
| Philip Hildale | Insulet | N/A | |
| Ezgi Yagci | Inspire Medical Systems | N/A | |
| Deborah CPA | Insulet | 53 | |
| Ivan Lubogo | Inspire Medical Systems | N/A | |
| MD FSIR | Penumbra | N/A | |
| Melissa Mann | Inspire Medical Systems | N/A | |
| Michael Comilla | Abbott Laboratories | N/A | |
| Jason Mills | Penumbra | N/A | |
| Tom Fox | Tandem Diabetes Care | N/A | |
| Melissa Brotz | Abbott Laboratories | N/A | |
| Andreas Henke | Inspire Medical Systems | N/A | |
| Sabina Ewing | Abbott Laboratories | 50 | |
| Prem Singh | Insulet | 47 | |
| Carlton Weatherby | Inspire Medical Systems | 39 | |
Management Performance
| Return On Equity | 0.0144 | ||||
| Return On Asset | 0.0073 |
Brainsway Leadership Team
Elected by the shareholders, the Brainsway's board of directors comprises two types of representatives: Brainsway inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brainsway. The board's role is to monitor Brainsway's management team and ensure that shareholders' interests are well served. Brainsway's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brainsway's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Jako, Pres CEO | ||
| Ido Marom, Chief Officer | ||
| Gilead Moiseyev, Chief Officer | ||
| Moria Ankri, VP RD | ||
| Pr Zangen, Member CoFounder | ||
| Hillegonda Groen, Vice Sales | ||
| Ross Mitchell, Vice Marketing | ||
| Richard MD, Chief Officer | ||
| Menachem Esq, General VP | ||
| Avner Hagai, Founder ViceChairman | ||
| Christopher Boyer, Vice Marketing | ||
| Hadar Levy, Chief Officer | ||
| Yiftach Roth, Chief Scientist | ||
| Aron Tendler, Chief Officer | ||
| Richard Areglado, VP CFO |
Brainsway Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Brainsway a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0144 | ||||
| Return On Asset | 0.0073 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 135.16 M | ||||
| Shares Outstanding | 18.78 M | ||||
| Shares Owned By Institutions | 19.22 % | ||||
| Number Of Shares Shorted | 30.6 K | ||||
| Price To Book | 4.21 X | ||||
| Price To Sales | 5.09 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Brainsway Stock Analysis
When running Brainsway's price analysis, check to measure Brainsway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainsway is operating at the current time. Most of Brainsway's value examination focuses on studying past and present price action to predict the probability of Brainsway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainsway's price. Additionally, you may evaluate how the addition of Brainsway to your portfolios can decrease your overall portfolio volatility.